Summary of Study ST003286
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002038. The data can be accessed directly via it's Project DOI: 10.21228/M85V5Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST003286 |
Study Title | Interaction between NSCLC cells, CD8+ T cells and immune checkpoint inhibitors potentiates coagulation and promotes metabolic remodeling- new cues on CAT-VTE |
Study Summary | Cancer-related thrombosis (CAT) and venous thromboembolism (VTE) are common cancer-related sequelae linked with high mortality, therefore finding predictive indicators is critical. Immune checkpoint inhibitors (ICI) are utilized in cancer immunotherapy to activate T lymphocytes against cancer cells. Recent retrospective investigations found that some individuals experienced increased VTE after receiving ICI. We postulated that ICI (anti-CTLA4 and anti-PD1) effect on immunological and cancer cells, as well as their interaction, contributes for an elevated risk of CAT-VTE. Our objective is to investigate this molecular interaction in order to uncover potential prothrombotic indicators. We pharmacologically modulated non-small cell lung cancer (NSCLC) cell lines in co-culture with CD8+ T lymphocytes (T CD8+) obtained from healthy blood donors. Nuclear Magnetic Resonance (NMR) metabolic remodeling analysis revealed differences in extracellular metabolite concentrations after T CD8+ and ICI treatment. |
Institute | ITQB NOVA |
Last Name | Gonçalves |
First Name | Luís |
Address | Avenida Republica |
lgafeira@itqb.unl.pt | |
Phone | 214469464 |
Submit Date | 2023-11-20 |
Raw Data Available | Yes |
Raw Data File Type(s) | fid |
Analysis Type Detail | NMR |
Release Date | 2024-07-03 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR002038 |
Project DOI: | doi: 10.21228/M85V5Z |
Project Title: | Interaction between NSCLC cells, CD8+ T cells and immune checkpoint inhibitors potentiates coagulation and promotes metabolic remodeling- new cues on CAT-VTE |
Project Summary: | Abstract Cancer-related thrombosis (CAT) and venous thromboembolism (VTE) are common cancer-related sequelae linked with high mortality, therefore finding predictive indicators is critical. Immune checkpoint inhibitors (ICI) are utilized in cancer immunotherapy to activate T lymphocytes against cancer cells. Recent retrospective investigations found that some individuals experienced increased VTE after receiving ICI. We postulated that ICI (anti-CTLA4 and anti-PD1) effect on immunological and cancer cells, as well as their interaction, contributes for an elevated risk of CAT-VTE. Our objective is to investigate this molecular interaction in order to uncover potential prothrombotic indicators. We pharmacologically modulated non-small cell lung cancer (NSCLC) cell lines in co-culture with CD8+ T lymphocytes (T CD8+) obtained from healthy blood donors. Nuclear Magnetic Resonance (NMR) metabolic remodeling analysis revealed differences in extracellular metabolite concentrations after T CD8+ and ICI treatment. |
Institute: | ITQB NOVA |
Last Name: | Gonçalves |
First Name: | Luís |
Address: | Avenida Republica |
Email: | lgafeira@itqb.unl.pt |
Phone: | 00351 214469464 |
Subject:
Subject ID: | SU003406 |
Subject Type: | Cultured cells |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Gender: | Not applicable |
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Sample source | Cell line | Culture Type | Immune checkpoint inhibitor |
---|---|---|---|---|---|
SA356220 | CD_A549_3_1_IPI3_rep3 | Non-small cell lung cancer cells | A549 | Direct Co-culture | Ipilimumab |
SA356221 | CD_A549_3_1_IPI3_rep1 | Non-small cell lung cancer cells | A549 | Direct Co-culture | Ipilimumab |
SA356222 | CD_A549_3_1_IPI3_rep2 | Non-small cell lung cancer cells | A549 | Direct Co-culture | Ipilimumab |
SA356223 | CD_A549_3_1_NIV3_rep3 | Non-small cell lung cancer cells | A549 | Direct Co-culture | Nivolumab |
SA356224 | CD_A549_TW_NIV2_rep2 | Non-small cell lung cancer cells | A549 | Direct Co-culture | Nivolumab |
SA356225 | CD_A549_3_1_NIV3_rep1 | Non-small cell lung cancer cells | A549 | Direct Co-culture | Nivolumab |
SA356226 | CD_A549_3_1_CTL3_rep3 | Non-small cell lung cancer cells | A549 | Direct Co-culture | No treatment |
SA356227 | CD_A549_TW_CTL2_rep2 | Non-small cell lung cancer cells | A549 | Direct Co-culture | No treatment |
SA356228 | CD_A549_3_1_CTL3_rep1 | Non-small cell lung cancer cells | A549 | Direct Co-culture | No treatment |
SA356229 | CD_A549_TW_IPI3_rep1 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | Ipilimumab |
SA356230 | CD_A549_TW_IPI3_rep2 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | Ipilimumab |
SA356231 | CD_A549_TW_IPI3_rep3 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | Ipilimumab |
SA356232 | CD_A549_NIV2_rep2 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | Nivolumab |
SA356233 | CD_A549_TW_NIV3_rep3 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | Nivolumab |
SA356234 | CD_A549_TW_NIV3_rep1 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | Nivolumab |
SA356235 | CD_A549_TW_CTL3_rep3 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | No treatment |
SA356236 | CD_A549_CTL2_rep2 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | No treatment |
SA356237 | CD_A549_TW_CTL3_rep1 | Non-small cell lung cancer cells | A549 | Indirect Co-culture | No treatment |
SA356238 | CD_A549_IPI3_rep3 | Non-small cell lung cancer cells | A549 | Monoculture | Ipilimumab |
SA356239 | CD_A549_IPI3_rep2 | Non-small cell lung cancer cells | A549 | Monoculture | Ipilimumab |
SA356240 | CD_A549_IPI3_rep1 | Non-small cell lung cancer cells | A549 | Monoculture | Ipilimumab |
SA356241 | CD_A549_NIV3_rep3 | Non-small cell lung cancer cells | A549 | Monoculture | Nivolumab |
SA356242 | CD_A549_NIV3_rep1 | Non-small cell lung cancer cells | A549 | Monoculture | Nivolumab |
SA356243 | CD_A549_3_1_NIV2_rep2 | Non-small cell lung cancer cells | A549 | Monoculture | Nivolumab |
SA356244 | CD_A549_3_1_CTL2_rep2 | Non-small cell lung cancer cells | A549 | Monoculture | No treatment |
SA356245 | CD_A549_CTL3_rep1 | Non-small cell lung cancer cells | A549 | Monoculture | No treatment |
SA356246 | CD_A549_CTL3_rep3 | Non-small cell lung cancer cells | A549 | Monoculture | No treatment |
SA356247 | CD_H292_TW_IPI1_rep2 | Non-small cell lung cancer cells | H292 | Direct Co-culture | Ipilimumab |
SA356248 | CD_H292_TW_IPI1_rep3 | Non-small cell lung cancer cells | H292 | Direct Co-culture | Ipilimumab |
SA356249 | CD_H292_TW_IPI1_rep1 | Non-small cell lung cancer cells | H292 | Direct Co-culture | Ipilimumab |
SA356250 | CD_H292_TW_NIV1_rep3 | Non-small cell lung cancer cells | H292 | Direct Co-culture | Nivolumab |
SA356251 | CD_H292_TW_NIV1_rep2 | Non-small cell lung cancer cells | H292 | Direct Co-culture | Nivolumab |
SA356252 | CD_H292_TW_NIV1_rep1 | Non-small cell lung cancer cells | H292 | Direct Co-culture | Nivolumab |
SA356253 | CD_H292_TW_CTL1_rep3 | Non-small cell lung cancer cells | H292 | Direct Co-culture | No treatment |
SA356254 | CD_H292_TW_CTL1_rep2 | Non-small cell lung cancer cells | H292 | Direct Co-culture | No treatment |
SA356255 | CD_H292_TW_CTL1_rep1 | Non-small cell lung cancer cells | H292 | Direct Co-culture | No treatment |
SA356256 | CD_H292_IPI1_rep3 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | Ipilimumab |
SA356257 | CD_H292_IPI1_rep2 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | Ipilimumab |
SA356258 | CD_H292_IPI1_rep1 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | Ipilimumab |
SA356259 | CD_H292_NIV1_rep3 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | Nivolumab |
SA356260 | CD_H292_NIV1_rep1 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | Nivolumab |
SA356261 | CD_H292_NIV1_rep2 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | Nivolumab |
SA356262 | CD_H292_CTL1_rep3 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | No treatment |
SA356263 | CD_H292_CTL1_rep2 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | No treatment |
SA356264 | CD_H292_CTL1_rep1 | Non-small cell lung cancer cells | H292 | Indirect Co-culture | No treatment |
SA356265 | CD_H292_3_1_IPI1_rep3 | Non-small cell lung cancer cells | H292 | Monoculture | Ipilimumab |
SA356266 | CD_H292_3_1_IPI1_rep2 | Non-small cell lung cancer cells | H292 | Monoculture | Ipilimumab |
SA356267 | CD_H292_3_1_IPI1_rep1 | Non-small cell lung cancer cells | H292 | Monoculture | Ipilimumab |
SA356268 | CD_H292_3_1_NIV1_rep3 | Non-small cell lung cancer cells | H292 | Monoculture | Nivolumab |
SA356269 | CD_H292_3_1_NIV1_rep2 | Non-small cell lung cancer cells | H292 | Monoculture | Nivolumab |
SA356270 | CD_H292_3_1_NIV1_rep1 | Non-small cell lung cancer cells | H292 | Monoculture | Nivolumab |
SA356271 | CD_H292_3_1_CTL1_rep2 | Non-small cell lung cancer cells | H292 | Monoculture | No treatment |
SA356272 | CD_H292_3_1_CTL1_rep1 | Non-small cell lung cancer cells | H292 | Monoculture | No treatment |
SA356273 | CD_H292_3_1_CTL1_rep3 | Non-small cell lung cancer cells | H292 | Monoculture | No treatment |
SA356274 | CD_PC9_3_1_IPI1_rep3 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | Ipilimumab |
SA356275 | CD_PC9_3_1_IPI1_rep2 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | Ipilimumab |
SA356276 | CD_PC9_3_1_IPI1_rep1 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | Ipilimumab |
SA356277 | CD_PC9_NIV1_rep3 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | Nivolumab |
SA356278 | CD_PC9_NIV1_rep2 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | Nivolumab |
SA356279 | CD_PC9_NIV1_rep1 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | Nivolumab |
SA356280 | CD_PC9_CTL1_rep3 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | No treatment |
SA356281 | CD_PC9_CTL1_rep2 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | No treatment |
SA356282 | CD_PC9_CTL1_rep1 | Non-small cell lung cancer cells | PC-9 | Direct Co-culture | No treatment |
SA356283 | CD_PC9_TW_IPI1_rep1 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | Ipilimumab |
SA356284 | CD_PC9_TW_IPI1_rep3 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | Ipilimumab |
SA356285 | CD_PC9_TW_IPI1_rep2 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | Ipilimumab |
SA356286 | CD_PC9_TW_NIV1_rep3 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | Nivolumab |
SA356287 | CD_PC9_TW_NIV1_rep2 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | Nivolumab |
SA356288 | CD_PC9_TW_NIV1_rep1 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | Nivolumab |
SA356289 | CD_PC9_TW_CTL3_rep3 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | No treatment |
SA356290 | CD_PC9_TW_CTL3_rep | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | No treatment |
SA356291 | CD_PC9_TW_CTL1_rep1 | Non-small cell lung cancer cells | PC-9 | Indirect Co-culture | No treatment |
SA356292 | CD_PC9_IPI3_rep3 | Non-small cell lung cancer cells | PC-9 | Monoculture | Ipilimumab |
SA356293 | CD_PC9_IPI3_rep2 | Non-small cell lung cancer cells | PC-9 | Monoculture | Ipilimumab |
SA356294 | CD_PC9_IPI3_rep1 | Non-small cell lung cancer cells | PC-9 | Monoculture | Ipilimumab |
SA356295 | CD_PC9_3_1_NIV1_rep3 | Non-small cell lung cancer cells | PC-9 | Monoculture | Nivolumab |
SA356296 | CD_PC9_3_1_NIV1_rep2 | Non-small cell lung cancer cells | PC-9 | Monoculture | Nivolumab |
SA356297 | CD_PC9_3_1_NIV1_rep1 | Non-small cell lung cancer cells | PC-9 | Monoculture | Nivolumab |
SA356298 | CD_PC9_3_1_CTL1_rep2 | Non-small cell lung cancer cells | PC-9 | Monoculture | No treatment |
SA356299 | CD_PC9_3_1_CTL1_rep3 | Non-small cell lung cancer cells | PC-9 | Monoculture | No treatment |
SA356300 | CD_PC9_3_1_CTL1_rep1 | Non-small cell lung cancer cells | PC-9 | Monoculture | No treatment |
Showing results 1 to 81 of 81 |
Collection:
Collection ID: | CO003399 |
Collection Summary: | Using Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA4), we pharmacologically modulated non-small cell lung cancer (NSCLC) cell lines in co-culture with CD8+ T lymphocytes (T CD8+) obtained from healthy blood donors. Two different modalities of co-cultures were established: direct and indirect (with T CD8+ separated from the cancer cells by a Boyden chamber with 1.0 μm pores). 1H-NMR spectroscopy was conducted to characterize the impact of the ICI in the metabolic profile of the immune and cancer cells, as well as the influence of immune cells in the cancer cells exometabolome. Therefore, the media obtained from the established cultures were centrifuged at 135 × g for 5 minutes and the supernatants were collected, stored at -80⁰C and later explored and defined by NMR. |
Sample Type: | Non-small cell lung cancer |
Treatment:
Treatment ID: | TR003415 |
Treatment Summary: | For the experimental conditions, cells were exposed to Nivolumab (10 mg/mL, OPDIVO), anti-PD1) or Ipilimumab (5 mg/mL, YERVOY, anti-CTLA-4) for 48 h. The Nivolumab and Ipilimumab concentrations were chosen in accordance to the posology indications from the European Medicines Agency (EMA) and using as reference a male adult with 80 kg and 5 L of blood. The conditions were tested in monoculture or in co-culture with TCD8+. |
Sample Preparation:
Sampleprep ID: | SP003413 |
Sampleprep Summary: | The supernatant samples were diluted in Milli-Q water to make up 540 μL (150 μL of water was added to 390 μL of supernatant). A volume of 30 µL of phosphate buffer was added to the samples along with 30 μL of a solution of 2.2 mM 3-(trimethylsilyl) propionic 2,2,3,3-d4 acid (TSP) in D2O. TSP was used as an internal reference for quantification and chemical shift. |
Analysis:
Analysis ID: | AN005383 |
Analysis Type: | NMR |
Num Factors: | 27 |
Num Metabolites: | 28 |
Units: | nanomoles |
NMR:
NMR ID: | NM000285 |
Analysis ID: | AN005383 |
Instrument Name: | Bruker Ultrashield 500 Plus |
Instrument Type: | FT-NMR |
NMR Experiment Type: | 1D-1H |
NMR Comments: | Spectra were acquired in a magnetic field of 500 MHz in an Ultrashied 500 Plus spectrometer (Bruker) with a TCI-Z probe at Instituto de Tecnologia Química e Biológica da Universidade NOVA de Lisboa (ITQB-UNL), Oeiras. The spectra analysis was made in TopSpin 4.1 software, according to Chenomx NMR suite 8.11 and Human Metabolome Database (HMDB). |
Spectrometer Frequency: | 500 MHz |
NMR Probe: | 5 mm prodigy TCI-z |
NMR Solvent: | 10% D2O/90% H20 |
NMR Tube Size: | 5 mm |